Does Minoxidil Work for Hair Loss?
This is a research-based fact check, not medical advice. The findings summarized here come from peer-reviewed studies and are presented without added opinions. Consult a certified healthcare practitioner before making any treatment decision.
Verdict
Yes. Topical minoxidil is FDA-approved for hair loss in men and women and is clinically proven to work. In a pivotal 48-week trial, 5% minoxidil produced 45% more hair regrowth than 2% minoxidil, with approximately 40-60% of users seeing significant improvement. About 16% of users in post-market studies rated 5% minoxidil as very effective and 48% as effective. Results require consistent, ongoing use: stopping treatment typically causes regrown hair to be lost within 3-6 months.
Key takeaways
- Topical minoxidil is FDA-approved for hair loss in men (1988) and women (1991) and is clinically proven to work.
- 5% minoxidil produced 45% more regrowth than 2% in a 48-week head-to-head trial (18.6 vs 12.7 nonvellus hairs added).
- 40-60% of users see significant improvement in clinical literature; about 16% rate 5% as very effective.
- Results take time: visible improvement typically starts at 2-4 months, with maximum effect at 6-12 months.
- Minoxidil requires continuous use: stopping causes regrown hair to be lost within 3-6 months.
- Minoxidil works for both men and women with pattern hair loss, though results tend to be more modest in women.
Clinical evidence for hair regrowth
Topical minoxidil is one of only two FDA-approved drug treatments for pattern hair loss (the other being finasteride, which is only approved for men). It has been in clinical use for pattern hair loss since 1988. An overview of all available hair loss treatments is in the hair restoration guide. For details on the full side effect profile and safety, see the minoxidil side effects guide.
The pivotal efficacy data comes from the Olsen 2002 trial: a 48-week, double-blind, placebo-controlled trial of 393 men with pattern hair loss. 5% minoxidil produced significantly more regrowth than both 2% minoxidil and placebo. Hair count data showed 5% added 18.6 nonvellus hairs in the target area vs 12.7 for 2% a 45% advantage. 5% was superior to 2% on 4 out of 6 efficacy measures and superior to placebo on all 6.
Efficacy rates from clinical studies
In post-market surveillance of 5% minoxidil, 15.9% of users rated it as very effective, 47.8% as effective, 20.6% as moderately effective, and 15.7% as ineffective. This gives a combined response rate of approximately 84%, though individual results vary considerably. Across the clinical literature, approximately 40-60% of patients see significant improvement with consistent topical minoxidil use.
These numbers reflect average outcomes. The degree of improvement depends on factors including how much hair loss has occurred, how long treatment has been used, consistency of application, and individual biological response to the drug.
What to expect from treatment
Treatment timeline
Visible improvement typically begins at 2-4 months of consistent use. Maximum results are usually seen at 6-12 months. Initial shedding in the first 2-8 weeks is normal and does not indicate treatment failure. In the Olsen 2002 trial, a faster response was observed with 5% compared to 2% minoxidil.
Measuring improvement
The primary clinical measure is nonvellus (visible, thickened) hair count in a defined target area. Trial participants typically see an increase of 12-19 hairs per square centimetre compared to placebo over 48 weeks. Global photographic assessment by dermatologists also shows improvement in the majority of treated patients, with changes more pronounced at the vertex (crown) than the frontal hairline.
Efficacy in women
Topical minoxidil is FDA-approved for women at 2% (since 1991) and 5% foam (since 2014). Efficacy data in women shows hair count improvements compared to placebo, though the magnitude of improvement is generally more modest than in men. Minoxidil is contraindicated during pregnancy. Unwanted facial hair growth is more commonly reported in women, particularly at higher concentrations.
Comparison with finasteride
Minoxidil and finasteride work through different mechanisms: minoxidil extends the hair growth cycle and improves follicle blood flow; finasteride blocks the hormone (DHT) that causes follicle miniaturisation. Network meta-analyses suggest finasteride and oral dutasteride may produce greater regrowth than topical minoxidil alone for male pattern hair loss. However, they are often prescribed together, and minoxidil is the only option suitable for both men and women. Finasteride is not FDA-approved for women.
Comparison with oral minoxidil
Oral minoxidil shows comparable hair density improvement to topical 5% in head-to-head trials, with no statistically significant difference. The main differences are side effects (oral causes more hypertrichosis) and regulatory status (oral is not FDA-approved for hair loss). Topical minoxidil remains the standard first-line recommendation.
Evidence at a glance
| Study | Patients | Key finding |
|---|---|---|
| Gupta 2015: topical minoxidil efficacy and safety review | Multiple RCTs | FDA-approved treatment with consistent evidence across trials. 40-60% significant improvement. |
| Gupta 2025 network meta-analysis: minoxidil vs finasteride vs dutasteride | Multiple RCTs | Topical minoxidil effective; finasteride and dutasteride may produce greater regrowth in men. |
| 2025 NMA: minoxidil combination therapies | Multiple RCTs | Minoxidil combined with other treatments (finasteride, microneedling) produces superior results to minoxidil alone. |
What the research cannot tell you
- Whether you personally will respond to minoxidil. No predictor of individual response exists.
- Whether hair regrown with minoxidil will return to baseline after stopping. Limited discontinuation data exists.
- Long-term outcomes beyond 5 years in controlled trials.
- How minoxidil efficacy changes with decades of continued use.
- The optimal concentration and formulation for your specific hair loss pattern.